サマリー

ライソゾーム病治療の世界市場は、2021年に75億7297万ドル、2031年には140億9039万ドルに達し、2022年から2031年までのCAGRは6.4％を記録すると予測されています。
ライソゾーム病は、ライソゾーム酸性リパーゼ酵素の欠乏または欠損によって引き起こされます。この酵素の欠乏により、リソソームの構造異常が生じ、体内の細胞内に様々な有害物質が蓄積されます。ライソゾーム病は約50種類あり、心臓、脳、皮膚、骨格、中枢神経系など様々な臓器に害を及ぼす可能性があります。さらに多くのライソゾーム病が発見され続けている。現在、いくつかのライソゾーム病の治療法の臨床試験が進行中ですが、多くのライソゾーム病は現在、承認された治療法がありません。

リソソーム貯蔵異常症として知られる一連の遺伝性代謝疾患は、さまざまな体細胞における酵素の欠損によって引き起こされます。ライソゾーム病治療市場の世界的な成長の主な要因は、ライソゾーム病を治療する希少薬開発に対する認識と財政的インセンティブの増加による診断率の向上です。また、ライソゾーム病の有病率の上昇、手頃な価格の製品コスト、ライソゾーム病を治療する新規薬剤の開発に対する製薬会社の増加も、市場の成長の要因となっています。ライソゾーム病の治療法の欠如と治療費の高騰は、市場の成長を抑制する要因となっています。

ライソゾーム病治療市場は、疾患タイプ、治療法のタイプ、エンドユーザー、地域に基づいて区分されます。疾患タイプ別に見ると、市場はゴーシェ病、ファブリー病、ポンペ症候群、ムコ多糖症、その他に分けられます。さらに、その他は、アスパルチルグルコサミン尿症、バッテン病、シスチン症、グリコーゲン貯蔵病IIに分類されています。治療法のタイプ別では、酵素補充療法、幹細胞療法、基質低減療法、その他に細分化されています。エンドユーザー別では、病院、診療所、その他に分類されます。地域別では、北米、欧州、アジア太平洋地域、LAMEAで分析されています。

世界のライソゾーム病治療市場で事業を展開する主な主要企業には、Amicus Therapeutics, Inc、Alexion Pharmaceuticals, Inc、BioMari、Chiese Farmaceutici SpA、Eli Lilly Company、Horizon Therapeutics Plc、Johnson & Johnson (Actelion Pharmaceuticals Ltd)、Actelion Pharmaceuticals Ltd., Inc.などがあります。Leadient Biosciences, Inc Novartis AG, Orphazyme A/S, Pfizer Inc, Recordati SpA, Sanofi (Genzyme Corporation), Sigilon Therapeutics, Inc, and Takeda Pharmaceutical Company Limited (Shire Plc) Valerion Therapeutics, Llc, and Viatris Inc (Mylan NV)があります。

ステークホルダーにとっての主なメリット
●ライソゾーム病治療薬市場の2021年から2031年までの市場セグメント、現在の動向、推定値、ダイナミクスを定量的に分析し、ライソゾーム病治療薬市場の有力な機会を特定することができます。
●市場調査は、主要な推進要因、阻害要因、機会に関連する情報とともに提供されます。
ライソゾーム病治療薬市場は、2021年から2031年まで、ライソゾーム病治療薬の市場機会を特定するために、市場調査を行っています。
ライソゾーム病治療薬市場の細分化に関する詳細な分析は、市場機会を決定するのに役立ちます。
ライソゾーム病治療薬市場の詳細な分析は、市場機会を決定するのに役立ちます。
市場プレイヤーのポジショニングにより、ベンチマークを容易にし、市場プレイヤーの現在のポジションを明確に理解することができます。
ライソゾーム病治療の地域および世界市場動向、キープレイヤー、市場セグメント、応用分野、市場成長戦略などの分析が含まれています。

主な市場セグメント
疾患タイプ別
ゴーシェ病
ファブリー病
ポンペ症候群
ムコ多糖症
その他
治療法別
酵素補充療法
幹細胞療法
基質低減療法
その他
エンドユーザー別
病院
クリニック
その他

地域別
北米
米国
カナダ
メキシコ
欧州
ドイツ
フランス
イギリス
イタリア
スペイン
その他の地域
アジア・パシフィック
日本
中国
オーストラリア
インド
韓国
その他のアジア太平洋地域
LAMEA
ブラジル
サウジアラビア
南アフリカ
LAMEAの残りの地域

主な市場関係者
アミカス・セラピューティック社
アレクシオン・ファーマシューティカルズ・インク
バイオマリン
ジョンソン・エンド・ジョンソン
ノバルティス
ファイザー
サノフィ
武田薬品工業株式会社
イーライリリー・アンド・カンパニー
シギロン・セラピューティック社

ページTOPに戻る

目次

CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key market segments
1.3.Key benefits to the stakeholders
1.4.Research Methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools and models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO Perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.3.Porter’s five forces analysis
3.4.Top player positioning
3.5.Market dynamics
3.5.1.Drivers
3.5.2.Restraints
3.5.3.Opportunities
3.6.COVID-19 Impact Analysis on the market
CHAPTER 4: LYSOSOMAL DISEASE TREATMENT MARKET, BY DISEASE TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Gaucher's Diseases
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Fabry Diseases
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Pompe’s Syndrome
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
4.5 Mucopolysaccharidosis
4.5.1 Key market trends, growth factors and opportunities
4.5.2 Market size and forecast, by region
4.5.3 Market analysis by country
4.6 Others
4.6.1 Key market trends, growth factors and opportunities
4.6.2 Market size and forecast, by region
4.6.3 Market analysis by country
CHAPTER 5: LYSOSOMAL DISEASE TREATMENT MARKET, BY TYPE OF THERAPY
5.1 Overview
5.1.1 Market size and forecast
5.2 Enzyme Replacement Therapy
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Stem Cell Therapy
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
5.4 Substrate Reduction Therapy
5.4.1 Key market trends, growth factors and opportunities
5.4.2 Market size and forecast, by region
5.4.3 Market analysis by country
5.5 Others
5.5.1 Key market trends, growth factors and opportunities
5.5.2 Market size and forecast, by region
5.5.3 Market analysis by country
CHAPTER 6: LYSOSOMAL DISEASE TREATMENT MARKET, BY END USER
6.1 Overview
6.1.1 Market size and forecast
6.2 Hospitals
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Clinics
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
6.4 Others
6.4.1 Key market trends, growth factors and opportunities
6.4.2 Market size and forecast, by region
6.4.3 Market analysis by country
CHAPTER 7: LYSOSOMAL DISEASE TREATMENT MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Disease Type
7.2.3 North America Market size and forecast, by Type of Therapy
7.2.4 North America Market size and forecast, by End User
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Disease Type
7.2.5.1.2 Market size and forecast, by Type of Therapy
7.2.5.1.3 Market size and forecast, by End User
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Disease Type
7.2.5.2.2 Market size and forecast, by Type of Therapy
7.2.5.2.3 Market size and forecast, by End User
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Disease Type
7.2.5.3.2 Market size and forecast, by Type of Therapy
7.2.5.3.3 Market size and forecast, by End User
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Disease Type
7.3.3 Europe Market size and forecast, by Type of Therapy
7.3.4 Europe Market size and forecast, by End User
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Disease Type
7.3.5.1.2 Market size and forecast, by Type of Therapy
7.3.5.1.3 Market size and forecast, by End User
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Disease Type
7.3.5.2.2 Market size and forecast, by Type of Therapy
7.3.5.2.3 Market size and forecast, by End User
7.3.5.3 U.K.
7.3.5.3.1 Market size and forecast, by Disease Type
7.3.5.3.2 Market size and forecast, by Type of Therapy
7.3.5.3.3 Market size and forecast, by End User
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Disease Type
7.3.5.4.2 Market size and forecast, by Type of Therapy
7.3.5.4.3 Market size and forecast, by End User
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Disease Type
7.3.5.5.2 Market size and forecast, by Type of Therapy
7.3.5.5.3 Market size and forecast, by End User
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Disease Type
7.3.5.6.2 Market size and forecast, by Type of Therapy
7.3.5.6.3 Market size and forecast, by End User
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Disease Type
7.4.3 Asia-Pacific Market size and forecast, by Type of Therapy
7.4.4 Asia-Pacific Market size and forecast, by End User
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Disease Type
7.4.5.1.2 Market size and forecast, by Type of Therapy
7.4.5.1.3 Market size and forecast, by End User
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Disease Type
7.4.5.2.2 Market size and forecast, by Type of Therapy
7.4.5.2.3 Market size and forecast, by End User
7.4.5.3 Australia
7.4.5.3.1 Market size and forecast, by Disease Type
7.4.5.3.2 Market size and forecast, by Type of Therapy
7.4.5.3.3 Market size and forecast, by End User
7.4.5.4 India
7.4.5.4.1 Market size and forecast, by Disease Type
7.4.5.4.2 Market size and forecast, by Type of Therapy
7.4.5.4.3 Market size and forecast, by End User
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Disease Type
7.4.5.5.2 Market size and forecast, by Type of Therapy
7.4.5.5.3 Market size and forecast, by End User
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Disease Type
7.4.5.6.2 Market size and forecast, by Type of Therapy
7.4.5.6.3 Market size and forecast, by End User
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Disease Type
7.5.3 LAMEA Market size and forecast, by Type of Therapy
7.5.4 LAMEA Market size and forecast, by End User
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Disease Type
7.5.5.1.2 Market size and forecast, by Type of Therapy
7.5.5.1.3 Market size and forecast, by End User
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Disease Type
7.5.5.2.2 Market size and forecast, by Type of Therapy
7.5.5.2.3 Market size and forecast, by End User
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Disease Type
7.5.5.3.2 Market size and forecast, by Type of Therapy
7.5.5.3.3 Market size and forecast, by End User
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Disease Type
7.5.5.4.2 Market size and forecast, by Type of Therapy
7.5.5.4.3 Market size and forecast, by End User
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 Amicus Therapeutics, Inc.
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 Alexion Pharmaceuticals, Inc
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 BioMarin
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 Johnson & Johnson
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 Novartis AG
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 Pfizer Inc.
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 Sanofi
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Takeda Pharmaceutical Company Limited
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Eli Lilly and Company
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 Sigilon Therapeutics, Inc
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments